Expression of prophybrotic markers TGF-β1, MMP-9 and FGFR in the kidneys of patients with urolithiasis during the development of chronic KIDNEY DISEASE

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: to evaluate the expression of profibrotic markers TGF-β1, MMP-9 and FGFR in the epithelium of proximal renal tubules in patients with urolithiasis depending on the composition of the nodule, as well as on the degree of decrease in the glomerular filtration rate (GFR).

Material and methods: complex examination of 17 patients with urolithiasis was carried out. Cockcroft-Gault formula for determining the glomerular filtration rate was used to estimate renal function, according to the results of which all patients were divided into 3 groups depending on the stage of GFR. Percutaneous nephrolithotripsy (PNLT) was performed according to the standard technique using laser treatment. The physical and chemical composition of the nodule was determined by polarization microscopy. All patients underwent morphological and morphometric study of nephrobiopsy specimens obtained at creation of puncture passage during PNLT in patients with nephrolithiasis. Immunohistochemical study was performed using profibrotic marker Anti-TGF beta 1 antibody (1:500, Abcam, UK), Anti-MMP-9 antibody (1:500, Abcam, UK), Anti-FGFR-1 1:50, Abcam, UK).

Results. Analysis of the results of morphological study revealed a correlation only between morphological manifestations of CPN progression and expression of profibrotic marker TGF-β.

Conclusion. The increase in TGF-β expression is accompanied by more pronounced atrophic changes in the epithelium of proximal renal tubules, which indicates the triggering of tubulointerstitial fibrosis mechanisms and the role of this marker in the progression of chronic kidney disease in patients with urolithiasis.

Full Text

Restricted Access

About the authors

A. M. Napsheva

Saratov State Medical University n.a. V.I.Razumovsky

Email: a.napsheva@yandex.ru
ORCID iD: 0000-0002-7471-4335

PhD, Assistant Professor of the Department of Pathological Anatomy

Russian Federation, Saratov

D. N. Khotko

Saratov State Medical University n.a. V.I.Razumovsky

Author for correspondence.
Email: dnksar@list.ru
ORCID iD: 0000-0002-7966-5181

PhD, Head of the Department of Urology, Senior Researcher at the Research Institute of Fundamental and Clinical Uronephrology

Russian Federation, Saratov

G. N. Maslyakova

Saratov State Medical University n.a. V.I.Razumovsky

Email: gmaslyakova@yandex.ru
ORCID iD: 0000-0001-8834-1536

Professor, DSc, Head of the Department of Pathological Anatomy

Russian Federation, Saratov

A. I. Tarasenko

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: tar-art@yandex.ru
ORCID iD: 0000-0002-3258-8174

Dr. Sc., Head of the Department of Urology

Russian Federation, Moscow

V. M. Popkov

Saratov State Medical University n.a. V.I.Razumovsky

Email: popkov.vm@staff.sgmu.ru
ORCID iD: 0000-0003-2876-9607

PhD, Deputy Director for Innovative Development

Russian Federation, Saratov

References

  1. Zdravoohranenie v Rossii. 2021: Stat.sb. - M.: Rosstat. Z-46. 2021; 171 p. Russian (Здравоохранение в России. 2021: Стат.сб./Росстат. - М., З-46, 2021. 171 с.).
  2. Sigurjonsdottir V.K., Runolfsdottir H.L., Indridason O.S., Palsson R., Edvardsson V.O. Impact of nephrolithiasis on kidney function. BMC Nephrol. 2015;16:149. doi: 10.1186/s12882-015-0126-1.
  3. Сhaussy C., Schüller J., Schmiedt E., Brandl H., Jocham D., Liedl B. Extracorporeal shock-wave lithotripsy (ESWL) for treatment of urolithiasis. Urology. 1984;23:59–66.
  4. Rule A.D., Bergstralh E.J., Melton L.J., Li X., Weaver A.L., Lieske J.C. Kidney stones and the risk for chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009;4:804–11. doi: 10.2215/CJN.05811108.
  5. Global burden of disease study, GBD, 2021. URL: https://www.healthdata.org/research-analysis/gbd
  6. Yamamoto T., Noble N.A., Miller D.E., Border W.A. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Border WA. Kidney Int. 1994;45(3):916–27. doi: 10.1038/ki.1994.122.
  7. Humphreys B.D. Mechanisms of Renal Fibrosis. Annual Review of Physiology. 2018;80(1):309–326. https://doi.org/10.1146/annurev-physiol-022516-034227
  8. Wu C.-F., Chiang W.-C., Lai C.-F., Chang F.C., Chen Y.T., Chou Y.H., Wu T.H., Linn G.R., Ling H., Wu K.D., Tsai T.J., Chen Y.M., Duffield J.S., Lin S.L. Transforming growth factor β-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol. 2013;182(1):118–31. doi: 10.1016/j.ajpath.2012.09.009.
  9. Lathan R. Exploring unconventional targets in my fibroblast trans differentiation outside classical TGF-β signaling in renal fibrosis Front Physiol. 2024;15:1296504. doi: 10.3389/fphys.2024.1296504.
  10. Xie Y., Su N., Yang J., Tan Q., Huang S., Jin M., Ni Z., Zhang B., D. Zhang, Luo F., Chen H., Sun X., Feng J.Q., Qi H., Chen L. FGF/FGFR signaling in health and disease. Signal Transduction and Targeted Therapy. 2020;5:181.
  11. Zhao H., Dong Y., Tian X. Tan T.K., Liu Z., Zhao Y., Zhang Y., Harris D.Ch., Zheng G. Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. World J Nephrol. 2013;2(3):84–89. doi: 10.5527/wjn.v2.i3.84.
  12. Koesters R., Kaissling B., Lehir M., Picard N., Theilig F., Gebhardt R., Glick A.B., Hähnel B., Hosser H., Gröne H.J., Kriz W. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol. 2010;177(2):632–43. doi: 10.2353/ajpath.2010.091012.
  13. Chen L., Yang T., Lu D.-W., Zhao H., Feng Y.L., Chen H., Chen D.Q., Vaziri N.D., Zhao Y.Y. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. Biomed Pharmacother. 2018;101:670–681. doi: 10.1016/j.biopha.2018.02.090.
  14. Kadlec A.O., Greco K.A., Fridirici Z.C., Gerber D, Turk TM. Effect of renal function on urinary mineral excretion and stone composition. Urology. 2011;78:744–47. doi: 10.1016/j.urology.2011.04.007.
  15. Musso C.G., Juarez R., Vilas M., Navarro M., Rivera H., Jauregui R. Renal calcium, phosphorus, magnesium and uric acid handling: comparison between stage III chronic kidney disease patients and healthy oldest old. Int Urol Nephrol. 2012;44:1559–62. doi: 10.1007/s11255-012-0230-0.
  16. Kang H.W., Seo S.P., Kim W.T., Kim Y.J., Yun S.J., Lee S.C., Kim W.J. Effect of renal insufficiency on stone recurrence in patients with urolithiasis. J Korean Med Sci. 2014;29(8):1132–37. doi: 10.3346/jkms.2014.29.8.1132.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Immunohistochemical reaction with TGF-1β antibody in patients with urolithiasis. Magnification 774.0

Download (233KB)
Indexing metadata

Copyright (c) 2024 Bionika Media